Cleo Diagnostics Company Profile - aVenture Research
Cleo Diagnostics
Cleo Diagnostics is a biotechnology company whose pre-surgical serum test, ordered through pathology providers, measures biomarkers for ovarian malignancy risk.
Cleo Diagnostics is a biotechnology company formed to commercialize novel technology for the detection of ovarian cancers, using technology discovered and developed at the Hudson Institute of Medical Research in Melbourne, Australia, and it is developing a portfolio of tests based on that same underlying technology.
The Pre-Surgical Triage Test uses a combination of serum biomarkers to determine malignancy risk before surgical referral for patients with a radiologically imaged adnexal mass, and a single serum test is ordered through a pathology provider with results returned directly to the physician office. The CleoDX test quantifies the CXCL10 active ratio alongside CA125, HE4 and IL6 to yield a numerical malignancy risk score, a serum biomarker panel for pathology providers and physician offices.